CD22 and Siglec-G regulate inhibition of B-cell signaling by sialic acid ligand binding and control B-cell tolerance

Glycobiology

Volumn 24, Issue 9, 2014, Pages 807-817

  Nitschke, Lars ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

autoimmunity; B lymphocytes; inhibitory signaling; Siglecs

Indexed keywords

CD22 ANTIGEN; ENZYME; SIALIC ACID; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; SIALYLTRANSFERASE; SIGLEC G; UNCLASSIFIED DRUG; LECTIN; LYMPHOCYTE ANTIGEN RECEPTOR; N ACETYLNEURAMINIC ACID; SIGLECG PROTEIN, MOUSE;

AUTOIMMUNITY; B CELL TOLERANCE; B LYMPHOCYTE; CD22 GENE; CELL MATURATION; CELLULAR PARAMETERS; DRUG TARGETING; GENE MUTATION; GENE TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNE RESPONSE GENE; IMMUNOLOGICAL TOLERANCE; INTRACELLULAR SIGNALING; LIGAND BINDING; LYMPHOCYTE FUNCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVIEW; SIGLECG GENE; ANIMAL; IMMUNOLOGY; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; AUTOIMMUNITY; B-LYMPHOCYTES; HUMANS; IMMUNE TOLERANCE; LECTINS; N-ACETYLNEURAMINIC ACID; RECEPTORS, ANTIGEN, B-CELL; SIALIC ACID BINDING IG-LIKE LECTIN 2; SIGNAL TRANSDUCTION;

EID: 84905511325     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwu066     Document Type: Review

References (92)

1. Abdu-Allah HH, Watanabe K, Completo GC, Sadagopan M, Hayashizaki K, Takaku C, Tamanaka T, Takematsu H, Kozutsumi Y, Paulson JC, et al. 2011. CD22-antagonists with nanomolar potency: The synergistic effect of hydrophobic groups at C-2 and C-9 of sialic acid scaffold. Bioorg Med Chem. 19:1966-1971.
2. Abdu-Allah HH, Watanabe K, Hayashizaki K, Takaku C, Tamanaka T, Takematsu H, Kozutsumi Y, Tsubata T, Ishida H, Kiso M. 2009. Potent small molecule mouse CD22-inhibitors: Exploring the interaction of the residue at C-2 of sialic acid scaffold. Bioorg Med Chem Lett. 19:5573-5575.
3. Adachi T, Harumiya S, Takematsu H, Kozutsumi Y, Wabl M, Fujimoto M, Tedder TF. 2012. CD22 serves as a receptor for soluble IgM. Eur J Immunol. 42:241-247.
4. Arming S, Wipfler D, Mayr J, Merling A, Vilas U, Schauer R, Schwartz-Albiez R, Vlasak R. 2011. The human Cas1 protein: A sialic acid-specific O-acetyltransferase? Glycobiology. 21:553-564.
5. Baumgarth N. 2011. The double life of a B-1 cell: Self-reactivity selects for protective effector functions. Nat Rev Immunol. 11:34-46.
6. Berland R, Wortis HH. 2003. Normal B-1a cell development requires B cell-intrinsic NFATc1 activity. Proc Natl Acad Sci USA. 100:13459-13464.
7. Blasius AL, Cella M, Maldonado J, Takai T, Colonna M. 2006. Siglec-H is an IPC-specific receptor that modulates type I IFN secretion through DAP12. Blood. 107:2474-2476.
8. Blixt O, Head S, Mondala T, Scanlan C, Huflejt ME, Alvarez R, Bryan MC, Fazio F, Calarese D, Stevens J, et al. 2004. Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci USA. 101:17033-17038.
9. Bökers S, Urbat A, Daniel C, Amann C, Smith KG, Espeli M, Nitschke L. 2014. Siglec-G Deficiency leads to more severe collagen-induced arthritis and earlier onset of lupus-like symptoms in MRL/lpr mice. J. Immunol. 192:2994-3002.
10. Boyd CR, Orr SJ, Spence S, Burrows JF, Elliott J, Carroll HP, Brennan K, Ni Gabhann J, Coulter WA, Jones C, et al. 2009. Siglec-E is up-regulated and phosphorylated following lipopolysaccharide stimulation in order to limit TLR-driven cytokine production. J Immunol. 183:7703-7709.
11. Cariappa A, Takematsu H, Liu H, Diaz S, Haider K, Boboila C, Kalloo G, Connole M, Shi HN, Varki N, et al. 2009. B cell antigen receptor signal strength and peripheral B cell development are regulated by a 9-O-acetyl sialic acid esterase. J Exp Med. 206:125-138.
12. Chen GY, Chen X, King S, Cavassani KA, Cheng J, Zheng X, Cao H, Yu H, Qu, Fang D, et al. 2011. Amelioration of sepsis by inhibiting sialidasemediated disruption of the CD24-SiglecG interaction. Nat Biotechnol. 29:428-435.
13. Chen GY, Tang J, Zheng P, Liu Y. 2009. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science. 323:1722-1725.
14. Chen WC, Completo GC, Sigal DS, Crocker PR, Saven A, Paulson JC. 2010. In vivo targeting of B-cell lymphoma with glycan ligands of CD22. Blood. 115:4778-4786.
15. Collins BE, Blixt O, DeSieno AR, Bovin N, Marth JD, Paulson JC. 2004. Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact. Proc Natl Acad Sci USA. 101:6104-6109.
16. Collins BE, Blixt O, Han S, Duong B, Li H, Nathan JK, Bovin N, Paulson JC. 2006. High-affinity ligand probes of CD22 overcome the threshold set by cis ligands to allow for binding, endocytosis, and killing of B cells. J Immunol. 177:2994-3003.
17. Collins BE, Smith BA, Bengtson P, Paulson JC. 2006. Ablation of CD22 in ligand-deficient mice restores B cell receptor signaling. Nat Immunol. 7:199-206.
18. Crocker PR, Paulson JC, Varki A. 2007. Siglecs and their roles in the immune system. Nat Rev Immunol. 7:255-266.
19. Cui Y, Sheng Y, Zhang X. 2013. Genetic susceptibility to SLE: Recent progress from GWAS. J Autoimmun. 41:25-33.
20. Deane JA, Pisitkun P, Barrett RS, Feigenbaum L, Town T, Ward JM, Flavell RA, Bolland S. 2007. Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity. 27:801-810.
21. Ding C, Liu Y, Wang Y, Park BK, Wang CY, Zheng P. 2007. Siglecg limits the size of B1a B cell lineage by down-regulating NFkappaB activation. PloS ONE. 2:e997.
22. Doody GM, Justement LB, Delibrias CC, Matthews RJ, Lin J, Thomas ML, Fearon DT. 1995. A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science. 269:242-244.
23. Duan B, Morel L. 2006. Role of B-1a cells in autoimmunity. Autoimmun Rev. 5:403-408.
24. Duong BH, Tian H, Ota T, Completo G, Han S, Vela JL, Ota M, Kubitz M, Bovin N, Paulson JC, et al. 2010. Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivo. J Exp Med. 207:173-187.
25. Engel P, Wagner N, Miller AS, Tedder TF. 1995. Identification of the ligandbinding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand. J Exp Med. 181:1581-1586.
26. Fujimoto M, Bradney AP, Poe JC, Steeber DA, Tedder TF. 1999. Modulation of B lymphocyte antigen receptor signal transduction by a CD19/CD22 regulatory loop. Immunity. 11:191-200.
27. Gerlach J, Ghosh S, Jumaa H, Reth M, Wienands J, Chan AC, Nitschke L. 2003. B cell defects in SLP65/BLNK-deficient mice can be partially corrected by the absence of CD22, an inhibitory coreceptor for BCR signaling. Eur J Immunol. 33:3418-3426.
28. Ghosh S, Bandulet C, Nitschke L. 2006. Regulation of B cell development and B cell signalling by CD22 and its ligands alpha2,6-linked sialic acids. Int Immunol. 18:603-611.
29. Grewal PK, Boton M, Ramirez K, Collins BE, Saito A, Green RS, Ohtsubo K, Chui D, Marth JD. 2006. ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling. Mol Cell Biol. 26:4970-4981.
30. Han S, Collins BE, Bengtson P, Paulson JC. 2005. Homomultimeric complexes of CD22 in B cells revealed by protein-glycan cross-linking. Nat Chem Biol. 1:93-97.
31. Hanasaki K, Powell LD, Varki A. 1995. Binding of human plasma sialoglycoproteins by the B cell-specific lectin CD22. Selective recognition of immunoglobulin M and haptoglobin. J Biol Chem. 270:7543-7550.
32. Harley IT, Kaufman KM, Langefeld CD, Harley JB, Kelly JA. 2009. Genetic susceptibility to SLE: New insights from fine mapping and genome-wide association studies. Nat Rev Genet. 10:285-290.
33. Hennet T, Chui D, Paulson JC, Marth JD. 1998. Immune regulation by the ST6Gal sialyltransferase. Proc Natl Acad Sci USA. 95:4504-4509.
34. Hoffmann A, Kerr S, Jellusova J, Zhang J, Weisel F, Wellmann U, Winkler TH, Kneitz B, Crocker PR, Nitschke L. 2007. Siglec-G is a B1 cell-inhibitory receptor that controls expansion and calcium signaling of the B1 cell population. Nat Immunol. 8:695-704.
35. Hutzler S, Özgör L, Naito-Matsui Y, Kläsener K, Winkler TW, Reth M, Nitschke L. 2014. The ligand-binding domain of Siglec-G is crucial for its selective inhibitory function on B1 cells. J Immunol. 192:5406-5414.
36. Jellusova J, Duber S, Guckel E, Binder CJ, Weiss S, Voll R, Nitschke L. 2010. Siglec-G regulates B1 cell survival and selection. J Immunol. 185:3277-3284.
37. Jellusova J, Nitschke L. 2012. Regulation of B cell functions by the sialic acidbinding receptors Siglec-G and CD22. Front Immunol. 2:96.
38. Jellusova J, Wellmann U, Amann K, Winkler TH, Nitschke L. 2010. CD22×Siglec-G double-deficient mice have massively increased B1 cell numbers and develop systemic autoimmunity. J Immunol. 184:3618-3627.
39. Kawasaki N, Rademacher C, Paulson JC. 2011. CD22 regulates adaptive and innate immune responses of B cells. J Innate Immun. 3:411-419.
40. Kelm S, Gerlach J, Brossmer R, Danzer CP, Nitschke L. 2002. The ligandbinding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound. J Exp Med. 195:1207-1213.
41. Kelm S, Madge P, Islam T, Bennett R, Koliwer-Brandl H, Waespy M, von Itzstein M, Haselhorst T. 2013. C-4 modified sialosides enhance binding to Siglec-2 (CD22): Towards potent Siglec inhibitors for immunoglycotherapy. Angew Chem Int Ed Engl. 52:3616-3620.
42. Kelm S, Pelz A, Schauer R, Filbin MT, Tang S, de Bellard ME, Schnaar RL, Mahoney JA, Hartnell A, Bradfield P, et al. 1994. Sialoadhesin, myelin-associated glycoprotein and CD22 define a new family of sialic aciddependent adhesion molecules of the immunoglobulin superfamily. Curr Biol. 4:965-972.
43. Kimura N, Ohmori K, Miyazaki K, Izawa M, Matsuzaki Y, Yasuda Y, Takematsu H, Kozutsumi Y, Moriyama A, Kannagi R. 2007. Human B-lymphocytes express alpha2-6-sialylated 6-sulfo-N-acetyllactosamine serving as a preferred ligand for CD22/Siglec-2. J BiolChem. 282:32200-32207.
44. Kono M, Ohyama Y, Lee YC, Hamamoto T, Kojima N, Tsuji S. 1997. Mouse beta-galactoside alpha 2,3-sialyltransferases: Comparison of in vitro substrate specificities and tissue specific expression. Glycobiology. 7:469-479.
45. Krauss J, Arndt MA, Vu BK, Newton DL, Seeber S, Rybak SM. 2005. Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion protein. Biochem Biophys Res Commun. 331:595-602.
46. Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJ, Wilson WH, Pastan I. 2005. Phase I trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol. 23:6719-6729.
47. Lajaunias F, Ibnou-Zekri N, Fossati Jimack L, Chicheportiche Y, Parkhouse RM, Mary C, Reininger L, Brighouse G, Izui S. 1999. Polymorphisms in the Cd22 gene of inbred mouse strains. Immunogenetics. 49:991-995.
48. Lanoue A, Batista FD, Stewart M, Neuberger MS. 2002. Interaction of CD22 with alpha2,6-linked ialoglycoconjugates: Innate recognition of self to dampen B cell autoreactivity? Eur J Immunol. 32:348-355.
49. Leonard JP, Goldenberg DM. 2007. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene. 26:3704-3713.
50. Ma DY, Suthar MS, Kasahara S, Gale M, Jr, Clark EA. 2013. CD22 is required for protection againstWest Nile virus Infection. J Virol. 87:3361-3375.
51. Macauley MS, Pfrengle F, Rademacher C, Nycholat CM, Gale AJ, von Drygalski A, Paulson JC. 2013. Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis. J Clin Invest. 123:3074-3083.
52. Mary C, Laporte C, Parzy D, Santiago ML, Stefani F, Lajaunias F, Parkhouse RM, O'Keefe TL, Neuberger MS, Izui S, et al. 2000. Dysregulated expression of the Cd22 gene as a result of a short interspersed nucleotide element insertion in Cd22a lupus-prone mice. J Immunol. 165:2987-2996.
53. Mesch S, Lemme K, Wittwer M, Koliwer-Brandl H, Schwardt O, Kelm S, Ernst B. 2011. From a library of MAG antagonists to nanomolar CD22 ligands. ChemMedChem. 7:134-143.
54. Müller J, Obermeier I, Wohner M, Brandl C, Mrotzek S, Angermuller S, Maity PC, Reth M, Nitschke L. 2013. CD22 ligand-binding and signaling domains reciprocally regulate B-cell Ca2+ signaling. Proc Natl Acad Sci USA. 110:12402-12407.
55. Naito-Matsui Y, Takada S, Kano Y, Iyoda T, Sugai M, Shimizu A, Inaba K, Nitschke L, Tsubata T, Oka S, et al. 2014. Functional evaluation of activation-dependent alterations in the sialoglycan composition of T cells. J Biol Chem. 289:1564-1579.
56. Naito Y, Takematsu H, Koyama S, Miyake S, Yamamoto H, Fujinawa R, Sugai M, Okuno Y, Tsujimoto G, Yamaji T, et al. 2007. Germinal center marker GL7 probes activation-dependent repression of N-glycolylneuraminic acid, a sialic acid species involved in the negative modulation of B-cell activation. Mol Cell Biol. 27:3008-3022.
57. Nitschke L. 2009. CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions. Immunol Rev. 230:128-143.
58. Nitschke L. 2013. Suppressing the antibody response with Siglec ligands. N Engl J Med. 369:1373-1374.
59. Nitschke L, Carsetti R, Ocker B, Kohler G, Lamers MC. 1997. CD22 is a negative regulator of B-cell receptor signalling. Curr Biol. 7:133-143.
60. Nitschke L, Floyd H, Ferguson DJ, Crocker PR. 1999. Identification of CD22 ligands on bone marrow sinusoidal endothelium implicated in CD22-dependent homing of recirculating B cells. J Exp Med. 189:1513-1518.
61. Nitschke L, Lajaunias F, Moll T, Ho L, Martinez-Soria E, Kikuchi S, Santiago-Raber ML, Dix C, Parkhouse RM, Izui S. 2006. Expression of aberrant forms of CD22 on B lymphocytes in Cd22a lupus-prone mice affects ligand binding. Int Immunol. 18:59-68.
62. O'Keefe TL, Williams GT, Batista FD, Neuberger MS. 1999. Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med. 189:1307-1313.
63. O'Keefe TL, Williams GT, Davies SL, Neuberger MS. 1996. Hyperresponsive B cells in CD22-deficient mice. Science. 274:798-801.
64. O'Reilly MK, Tian H, Paulson JC. 2011. CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells. J Immunol. 186:1554-1563.
65. Onodera T, Poe JC, Tedder TF, Tsubata T. 2008. CD22 regulates time course of both B cell division and antibody response. J Immunol. 180:907-913.
66. Otipoby KL, Andersson KB, Draves KE, Klaus SJ, Farr AG, Kerner JD, Perlmutter RM, Law CL, Clark EA. 1996. CD22 regulates thymus-independent responses and the lifespan of B cells. Nature. 384:634-637.
67. Otipoby KL, Draves KE, Clark EA. 2001. CD22 regulates B cell receptormediated signals via two domains that independently recruit Grb2 and SHP-1. J Biol Chem. 276:44315-44322.
68. Peaker CJ, Neuberger MS. 1993. Association of CD22 with the B cell antigen receptor. Eur J Immunol. 23:1358-1363.
69. Pfrengle F, Macauley MS, Kawasaki N, Paulson JC. 2013. Copresentation of antigen and ligands of Siglec-G induces B cell tolerance independent of CD22. J Immunol. 191:1724-1731.
70. Poe JC, Fujimoto M, Jansen PJ, Miller AS, Tedder TF. 2000. CD22 forms a quaternary complex with SHIP, Grb2, and Shc. A pathway for regulation of B lymphocyte antigen receptor-induced calcium flux. J Biol Chem. 275:17420-17427.
71. Poe JC, Fujimoto Y, Hasegawa M, Haas KM, Miller AS, Sanford IG, Bock CB, Fujimoto M, Tedder TF. 2004. CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms. Nat Immunol. 5:1078-1087.
72. Powell LD, Sgroi D, Sjoberg ER, Stamenkovic I, Varki A. 1993. Natural ligands of the B cell adhesion molecule CD22 beta carry N-linked oligosaccharides with alpha-2,6-linked sialic acids that are required for recognition. J Biol Chem. 268:7019-7027.
73. Prescher H, Schweizer A, Kuhfeldt E, Nitschke L, Brossmer R. 2014. Discovery of multifold modified sialosides as human CD22/Siglec-2 ligands with nanomolar activity on B cells. ACS Chem Biol. PMID: 24807582.
74. Ramya TN, Weerapana E, Liao L, Zeng Y, Tateno H, Yates JR, 3rd, Cravatt BF, Paulson JC. 2010. In situ trans ligands of CD22 identified by glycan-protein photocross-linking-enabled proteomics. Mol Cell Proteomics. 9:1339-1351.
75. Razi N, Varki A. 1998. Masking and unmasking of the sialic acid-binding lectin activity of CD22 (Siglec-2) on B lymphocytes. Proc Natl Acad Sci USA. 95:7469-7474.
76. Samardzic T, Marinkovic D, Danzer CP, Gerlach J, Nitschke L, Wirth T. 2002. Reduction of marginal zone B cells in CD22-deficient mice. Eur J Immunol. 2:561-567.
77. Sato S, Miller AS, Inaoki M, Bock CB, Jansen PJ, Tang ML, Tedder TF. 1996. CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: Altered signaling in CD22-deficient mice. mmunity. 5:551-562.
78. Schweizer A, Wohner M, Prescher H, Brossmer R, Nitschke L. 2013. Targeting of CD22-positive B-cell lymphoma cells by synthetic divalent sialic acid analogues. Eur J Immunol. 42:2792-2802.
79. Sgroi D, Koretzky GA, Stamenkovic I. 1995. Regulation of CD45 engagement by the B-cell receptor CD22. Proc Natl Acad Sci USA. 92:4026-4030.
80. Sieger N, Fleischer SJ, Mei HE, Reiter K, Shock A, Burmester GR, Daridon C, Dorner T. 2013. CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation. Arthritis Rheum. 65:770-779.
81. Sjoberg ER, Powell LD, Klein A, Varki A. 1994. Natural ligands of the B cell adhesion molecule CD22 beta can be masked by 9-O-acetylation of sialic acids. J Cell Biol. 126:549-562.
82. Smith KGC, Tarlinton DM, Doody GM, Hibbs ML, Fearon DT. 1998. Inhibition of the B cell by CD22: A requirement for Lyn. J Exp Med. 187:807-811.
83. Surolia I, Pirnie SP, Chellappa V, Taylor KN, Cariappa A, Moya J, Liu H, Bell DW, Driscoll DR, Diederichs S, et al. 2010. Functionally defective germline variants of sialic acid acetylesterase in autoimmunity. Nature. 466:243-247.
84. Takashima S. 2008. Characterization of mouse sialyltransferase genes: Their evolution and diversity. Biosci Biotechnol Biochem. 72:1155-1167.
85. Torres RM, Law CL, Santos-Argumedo L, Kirkham PA, Grabstein K, Parkhouse RM, Clark EA. 1992. Identification and characterization of the murine homologue of CD22, a B lymphocyte-restricted adhesion molecule. J Immunol. 149:2641-2649.
86. Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A. 2003. Activation of autoreactive B cells by CpG dsDNA. Immunity. 19:837-847.
87. Wallace DJ, Kalunian K, Petri MA, Strand V, Houssiau FA, Pike M, Kilgallen B, Bongardt S, Barry A, Kelley L, et al. 2014. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: Results from EMBLEM, a phase IIb, randomised, double-blind, placebocontrolled, multicentre study. Ann Rheum Dis. 73:183-190.
88. Wang X, Vertino A, Eddy RL, Byers MG, Jani-Sait SN, Shows TB, Lau JT. 1993. Chromosome mapping and organization of the human beta-galactoside alpha 2,6-sialyltransferase gene. Differential and cell-type specific usage of upstream exon sequences in B-lymphoblastoid cells. J Biol Chem. 268:4355-4361.
89. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. 2003. Predominant autoantibody production by early human B cell precursors. Science. 301:1374-1377.
90. Wen T, Mingler MK, Blanchard C, Wahl B, Pabst O, Rothenberg ME. 2012. The pan-B cell marker CD22 is expressed on gastrointestinal eosinophils and negatively regulates tissue eosinophilia. J Immunol. 188:1075-1082.
91. Whitney G, Wang S, Chang H, Cheng KY, Lu P, Zhou XD, Yang WP, McKinnon M, Longphre M. 2001. A new Siglec family member, Siglec-10, is expressed in cells of the immune system and has signaling properties similar to CD33. Eur J Biochem. 268:6083-6096.
92. Zhang M, Varki A. 2004. Cell surface sialic acids do not affect primary CD22 interactions with CD45 and surface IgM nor the rate of constitutive CD22 endocytosis. Glycobiology. 14:939-949.